Equibles does not estimate personal net worth.
Get an email with a short summary when Definium Therapeutics, Inc. publishes a filing, an earnings call transcript or a press release.
Get DFTX alertsRobert Barrow is recorded as CEO at Definium Therapeutics, Inc. (DFTX). The newest filing on record that lists Robert Barrow as CEO at Definium Therapeutics, Inc. (DFTX) is dated April 27, 2026. Definium Therapeutics, Inc. reported in an 8-K filed June 12, 2026 that Robert Barrow was appointed Director, effective June 11, 2026. Definium Therapeutics, Inc. reported in an 8-K filed June 16, 2025 that Robert Barrow was appointed member of the Board, effective June 12, 2025. The proxy statement of Definium Therapeutics, Inc. reports total compensation of $12,767,442 for Robert Barrow in fiscal 2025, including a base salary of $655,000. Disclosed compensation is on record for 3 fiscal years. Robert Barrow has spoken on 5 earnings calls across 1 company, most recently for Definium Therapeutics, Inc. on June 22, 2026. Definium Therapeutics, Inc. is classified in the Biotechnology industry within the Healthcare sector. Other leadership on record at Definium Therapeutics, Inc. includes Dr. Roger Crystal (CEO), Dr. Suzanne Bruhn (CEO), JR Rahn (CEO) and 7 others.
“The Company's seven nominees, Robert Barrow, Dr. Suzanne Bruhn, Dr. Roger Crystal, David Gryska, Andreas Krebs, Carol A. Vallone, and Roger Adsett, were each elected to serve as a member of the Board until the 2027 annual general meeting of shareholders (the "2027 Annual Meeting") or until a successor has been duly elected or appointed, by the following votes:”
“The Company's six nominees, Robert Barrow, Dr. Suzanne Bruhn, Dr. Roger Crystal, David Gryska, Andreas Krebs, and Carol A. Vallone, were each elected to serve as a member of the Board until the 2026 annual general meeting of shareholders (the "2026 Annual Meeting") and until his or her successor is duly elected or qualified, by the following votes:”
“The first quarter of 2026 marked a strong start to what we believe will be a pivotal year for DefiniM.”
“I'm very pleased with our overall performance and execution through the first half of the year.”
“The press release reporting our financial results is available in the Investors and Media section of our website and our quarterly report on Form 10-Q for the quarter ended September 30, 2023, will be filed today with the Securities and Exchange Commission.”
“Welcome to our fourth quarter and full year 2022 financial results and corporate update conference call.”
“Welcome to MindMed's Third Quarter 2022 Financial Results and Corporate Update Conference Call. Prior to market open today, we issued a press release with a summary of our results for the third quarter of 2022.”
Start not stated–present
Last confirmed April 27, 2026
2021-01-01–2025-04-23
Last confirmed by a filing; no departure on record
Biotechnology · Healthcare
CEO
2021-01-01–present
Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.
| Fiscal year | Company | Role | Salary | Total |
|---|---|---|---|---|
| 2025 | Definium Therapeutics, Inc. (DFTX) | Chief Executive Officer | $655,000 | $12,767,442 |
| 2024 | Definium Therapeutics, Inc. (DFTX) | Chief Executive Officer | $623,500 | $2,669,010 |
| 2021 | Definium Therapeutics, Inc. (DFTX) | Chief Executive Officer | $350,000 | $11,889,466 |
